June 28, 2024 03:06 PM EDT

CMS spells out how states can join new cell and gene therapy access pilot

Zachary Brennan

Senior Editor

The Centers for Medicare and Medicaid Services plans to begin testing whether outcomes-based agreements might improve access to two new gene therapies approved for sickle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CMS spells out how states can join new cell and gene therapy access pilot

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

CMS spells out how states can join new cell and gene ther­a­py ac­cess pi­lot

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

CMS spells out how states can join new cell and gene therapy access pilot

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B